Provided by Tiger Trade Technology Pte. Ltd.

Chemomab Therapeutics Ltd.

2.16
+0.09004.35%
Post-market: 2.12-0.0400-1.85%16:10 EDT
Volume:114.19K
Turnover:242.62K
Market Cap:15.83M
PE:-2.15
High:2.20
Open:2.06
Low:2.04
Close:2.07
52wk High:4.12
52wk Low:1.35
Shares:7.33M
Float Shares:6.14M
Volume Ratio:2.02
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0070
EPS(LYR):-1.4103
ROE:-82.17%
ROA:-46.27%
PB:1.82
PE(LYR):-1.53

Loading ...

Press Release: Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
May 14

Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
May 11

Chemomab Therapeutics holds annual shareholders meeting, re-elects directors

Reuters
·
May 07

Chemomab Therapeutics director Neil Cohen files initial beneficial ownership statement

Reuters
·
Apr 11

Chemomab Therapeutics files Form 3 as director Nissim Darvish reports holdings

Reuters
·
Apr 11

Chemomab files Form 3 for CFO Fatal Sigal’s initial beneficial ownership stake

Reuters
·
Apr 11

Chemomab files Form 3 for Chief Development Officer John Lawler

Reuters
·
Apr 11

Chemomab files initial beneficial ownership statement for director Claude Nicaise

Reuters
·
Apr 01

Chemomab files Form 3 for director Jill Quigley’s beneficial ownership statement

Reuters
·
Apr 01

Maxim Group Remains a Buy on Chemomab Therapeutics (CMMB)

TIPRANKS
·
Mar 20

Chemomab FY 2025 net loss fell 35.5% to USD 9 million

Reuters
·
Mar 19

Chemomab Therapeutics: Evaluating Additional Therapeutic Indications Where Nebokitug Has Generated Robust Preclinical Efficacy Signals

THOMSON REUTERS
·
Mar 19

Chemomab Therapeutics Q4 Operating Expenses USD 1.974 Million

THOMSON REUTERS
·
Mar 19

Press Release: Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Dow Jones
·
Mar 19

Chemomab Therapeutics Ltd expected to post a loss of 31 cents a share - Earnings Preview

Reuters
·
Feb 27